What is HC Wainwright’s Forecast for AUTL Q3 Earnings?

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of Autolus Therapeutics in a research note issued to investors on Monday, November 2nd. HC Wainwright analyst D. Tsao anticipates that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.73) EPS and FY2030 earnings at ($0.26) EPS.

Several other analysts have also recently commented on the stock. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Autolus Therapeutics Price Performance

NASDAQ:AUTL opened at $1.42 on Wednesday. The company’s 50-day moving average is $1.87 and its two-hundred day moving average is $1.67. The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The firm has a market cap of $376.62 million, a price-to-earnings ratio of -1.33 and a beta of 2.32. Autolus Therapeutics has a 12-month low of $1.18 and a 12-month high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.06. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. The firm had revenue of $45.69 million during the quarter, compared to the consensus estimate of $38.56 million.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AUTL. Syncona Portfolio Ltd purchased a new stake in Autolus Therapeutics during the 2nd quarter worth $26,625,152. Cetera Investment Advisers raised its stake in Autolus Therapeutics by 2.7% during the first quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock valued at $1,558,000 after buying an additional 29,324 shares in the last quarter. Alphabet Inc. bought a new position in Autolus Therapeutics during the 2nd quarter worth approximately $1,117,000. Privium Fund Management B.V. lifted its holdings in Autolus Therapeutics by 29.2% during the 3rd quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock worth $911,000 after buying an additional 106,060 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its position in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after acquiring an additional 11,197 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.